The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: sanofi-aventis Canada

Monday Biotech Deal Review: July 25, 2011

Welcome to your Monday Biotech Deal Review for July 25, 2011.  Interesting tidbits from last week included the termination of the letter of intent relating to the proposed reverse-takeover transaction between Bradmer Pharmaceuticals and P1 Energy Corp., a distribution and marketing agreement between Valeant and Sanofi-aventis Canada, a $15M loan agreement between Protox Therapeutics and Oxford Finance LLC, the filing of a preliminary short-form base shelf prospectus in the Canada and U.S. by YM BioSciences, the closing of a $7M financing round for gIcare Pharma Inc., and the acquisition by Paladin Labs of a significant number of common shares of Afexa Life Sciences.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: May 10, 2010

Some people were on the move this week — not only did Sanofi Canada announce 70 R&D job cuts, but BioMS took on a new banker and Labopharm, CardioComm and GeneNews all get new faces. Despite the fact that it seemed half of the country’s companies and deal-makers were at BIO in Chicago this week, there was still a fair amount of positive deal activity including numerous private placements, commercial agreements and a bit of M&Eh.

Read more of this post

Monday Biotech Deal Review: December 7, 2009

This was a fairly busy week for Canadian biotech deals, including a new brain-y collaboration for MaRS; peace at Patheon; some overallotment and some underallotment; some diversification by Canadian pharma (even if not on quite the scale of Pfizer’s deal with Protalix); and some trans-Atlantic acquisitiveness of a Canadian company’s own devicing [sic., sorry].  Don’t stop now… Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 129 other followers